Clinical Trials Directory

Trials / Completed

CompletedNCT02695966

EVIS - Ex-vivo Assessment of T-lymphocyte Homing in Primary Pancreatic Cancer

A Feasibility Study Assessing the Ability of an Ex-vivo Assay to Measure AMD3100's Ability to Overcome Tumour Immune-privilege and Bring T-lymphocytes Into Contact With Neoplastic Targets.

Status
Completed
Phase
Study type
Observational
Enrollment
20 (actual)
Sponsor
Cambridge University Hospitals NHS Foundation Trust · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a single-centre, prospective, non-randomised research study. The research team will investigate the feasibility of assessing primary human pancreatic tissue for changes to T lymphocyte function and localisation in the presence and absence of AMD3100.

Detailed description

Pancreatic cancer is the fourth leading cause of cancer-related deaths in Western countries. It is a lethal disease that typically presents late, metastasises early and is resistant to conventional treatments such as radiation and chemotherapy. In 2012 there were 8700 deaths in the UK from pancreatic cancer, making it the fifth most common cause of cancer-related death. Current therapeutic strategies are aimed at extending survival as well as improving symptoms and quality of life, but although conventional chemotherapeutic agents have achieved modest clinical benefit, the need for novel therapies is great. This study proposes to extend our pre-clinical studies to develop an ex-vivo assay for the assessment of AMD3100 effectiveness in human samples. The research team will investigate the feasibility of assessing primary human pancreatic tissue for changes to T lymphocyte function and localisation in the presence and absence of AMD3100 through obtaining a blood sample and fresh pancreatic tissue intra-operatively from pancreatic tumours located in the head of the pancreas.

Conditions

Interventions

TypeNameDescription
PROCEDUREWhipples SurgeryWhipples Surgery

Timeline

Start date
2015-05-01
Primary completion
2018-07-01
Completion
2018-07-01
First posted
2016-03-02
Last updated
2019-07-16

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02695966. Inclusion in this directory is not an endorsement.